Read twice and referred to the Committee on Finance.
Email me when S 5571 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track S 5571. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The Biosimilars Access and Affordability Act changes the timing that biosimilar biological products become eligible for Medicare price negotiations, allowing the Secretary of Health and Human Services to delay their inclusion under certain conditions. It also creates a rebate mechanism if a biosimilar is not marketed within the delay period. The bill affects drug manufacturers, Medicare beneficiaries, and the federal budget by potentially lowering drug costs.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about S 5571
3 free questions a day, no accountSponsors
- Sen. Blackburn, Marsha [R-TN] (R) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when S 5571 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track S 5571 freeOr ask your AI assistant about S 5571 directly:
Add to Claude, ChatGPT or Cursor